www.tmepharma.com

Improving Therapeutic Outcomes by Targeting the Tumor Microenvironment

April 2024



April 2024 © TME Pharma

Forward Looking Statements



The information and opinions contained in this presentation and any other information discussed at this presentation are provided as at the date of this presentation and are therefore of a preliminary nature, have not been independently verified and may be subject to updating, revision, amendment or change without notice and in some cases has not been audited or reviewed by the Company's auditors. This presentation is selective in nature and does not purport to contain all information that may be required to evaluate the Company and/or its securities. Neither the Company nor any other person is under any obligation to update or keep current the information contained in this presentation or to correct any inaccuracies in any such information which may become apparent or to provide you with any additional information. No reliance may or should be placed for any purpose whatsoever on the information contained in this presentation, or any other information discussed verbally, or on its completeness, accuracy or fairness. None of the Company, its investment banking representatives, or any of their respective directors,


officers, employees, direct or indirect shareholders, agents, affiliates, advisors or any other person accept any responsibility whatsoever for the contents of this presentation, and no representation or warranty, express or implied, is made by any such person in relation to the contents of this presentation.

Certain information in this presentation is based on management estimates. Such estimates have been made in good faith and represent the current beliefs of applicable members of management. Those management members believe that such estimates are founded on reasonable grounds. However, by their nature, estimates may not be correct or complete. Accordingly, no representation or warranty (express or implied) is given that such estimates are correct or complete. Where this presentation quotes any information or statistics from any external source, it should not be interpreted that the Company has adopted or endorsed such information or statistics as being accurate. This

presentation contains forward looking statements. These statements reflect the Company's current knowledge and its expectations and projections about future events and may be identified by the context of such statements or words such as "anticipate," "believe", "estimate", "expect", "intend", "plan", "project", "target", "may", "will", "would", "could", "might" or "should" or similar terminology. By their nature, forward looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company's control that could cause the Company's actual results and performance to differ materially from any expected future results or performance expressed or implied by any forward looking statements. The Company undertakes no obligation to publicly release the results of any revisions to any forward looking statements in this presentation that may occur due to any change in its expectations or to reflect events or circumstances after the date of this presentation.

Strong Value Proposition Through Differentiated Pipeline Targeting the Tumor Microenvironment





Financial Profile



TME Pharma is listed on Euronext Growth Paris – ALTME

- Highly efficient structure with 14 employees and key expertise in-house
- Cash & equivalents:
- €3 million (30 June 2023)
- ~€5.15 million gross additional raised since 30 June 2023
- Financial visibility into July 2024


FINANCIALS AND SHAREHOLDING STRUCTURE

Public listing	2016			
ISIN Code	NL0015000YE1			
Ticker	ALTME			
Market	Euronext Growth Paris			
Market Cap*	€8.9 M			
Shares outstanding*	28,453,373			
Warrants Z ISIN	NL0015001SR3			
Warrants Z outstanding*	3,326,104			
*As of March 28, 2024, yielding up to 4,157,630 more shares				

NOX-A12 Combinations Improve Best Response Rates and Depth of Tumor Shrinkage vs. Standard of Care



(Matched reference cohort from center participating in trial: MGMT Unmethylated & incomplete surgical resection or biopsy only)



Radiotherapy + NOX-A12

Sources: Giordano (2022) ASCO Annual Meeting Presentation #2050; Giordano (2022) SNO Annual Meeting Poster Presentation #CTNI-67, Giordano (2023) ASCO Annual Meeting Poster Presentation #405 & TME Pharma Press Release from 19 November 2022, 26 May 2023, 13 July 2023, 2 February 2024


5

Radiotherapy + NOX-A12

+ anti-VEGF

10-Fold Improvement in 21-month Survival for NOX-A12 + RT + anti-VEGF vs. Standard of Care





Since neither bevacizumab (anti-VEGF) alone, nor bevacizumab plus radiotherapy have previously been shown to extend survival², the strong increase in survival can be attributed to the complementary mechanism of action of NOX-A12 with bevacizumab and radiotherapy

1. Standard of care data from 20-patient matched reference cohort of newly diagnosed glioblastoma with MGMT unmethylated, incompletely resected or biopsy-only tumors; Giordano (2022) ASCO Annual Meeting Pres. #2050. NOX-A12 survival data from *TME Pharma* Press Release 2 February 2024; 2. Chinot (2014) NEJM, Gilbert (2014) NEJM, Herrlinger (2016) J Clin Oncology

Spiegelmer[®] Platform: Next-Generation RNA Aptamers



Spiegelmer (Blue) **Chemokine Target** Protein (Red)

Chemokines are like street-signs in the body for moving cells, they are anchored (location information) and display instructions e.g. ("enter here") for moving cells that can "see" them with the appropriate receptors.

RNA aptamers made with L-stereoisomer bind their targets with affinity similar or higher than antibodies and come with key benefits:

- Natural resistance to nuclease degradation no chemical modification of backbone needed
- Large interaction surface enables complete inhibition of both key chemokine domains: receptor activation & anchoring for location



Pipeline Assets Complement Anti-Cancer Therapies to Enhance Treatment Efficacy



Therapy & Indication	Preclinical	Phase 1/2	Phase 2	Phase 3	Next Inflection Point	Partner/ Collaborator
NOX-A12 + Radiotherapy ± anti-VEGF Brain cancer / Glioblastoma Orphan Drug Designation US & EU			Protocol approved & Fast Track designation awarded by FDA		Financing and initiation of randomized Ph 2	
NOX-A12 + Immunotherapy Pancreatic Cancer			Protocol approved in FR, ES & US		Financing and initiation of randomized Ph 2	Scientific Collaborator for Ph 1/2 & Ph 2
NOX-E36 Combinations Solid Tumors De-risked by completed Phase 1 and Phase 2a study (diabetic nephropathy)						

Trial completed

Trial ongoing or in preparation

All timelines subject to financing and patient recruitment

NOX-A12 (olaptesed pegol) is an injectable PEG-conjugated L-stereoisomer RNA aptamer that directly binds and neutralizes the chemokine CXCL12, preventing signaling through its two receptors CXCR4 & CXCR7. NOX-A12 also de-anchors the chemokine, destroying its gradient forming capacity.

NOX-E36 (emapticap pegol) is an injectable PEG-conjugated L-stereoisomer RNA aptamer conjugated to 40kD PEG that directly binds and neutralizes the chemokine CCL2, preventing signaling through its receptor CCR2. NOX-E36 also de-anchors the chemokine, destroying its gradient forming capacity.

Experienced Biopharma Team





Aram Mangasarian Chief Executive Officer

- 20+ years experience in biotech
- ~€65m raised for TME Pharma - Novexel: €150m license with Forest & \$505m acquisition by AZ ExonHit: \$30m alliance with Allergan



- **Ewelina Staniuk** Sr Director, IR & BD
- 10+ years in international projects - Portfolio of financing & partnering opportunities
- Design and execution of corporate communication



- Jarl Ulf Jungnelius, MD Chief Medical Officer
- Oncologist with 25+ years clinical & research experience
- Isofol, Celgene, Takeda, Pfizer, Eli Lilly
- Approvals of Alimta[®], Revlimid[®], Abraxane[®] & Gemzar[®]

MANAGEMENT



Heike Balzer SVP Finance

- 20+ years experience in corporate finance
- Execution of investments for over €190m
- Lecturer at the Potsdam University



Dirk Eulberg SVP Project Management

- 20+ years experience in biotech - Development of 3 drugs from discovery to clinic - Lead role in big pharma and



Karen Ophoff VP HR & Legal, General Counsel

- 20+ years experience in legal & corporate matters, incl. Euronext **Growth** listing
- Negotiation & execution of transactions for over €190m



Chairman of the Board **Maurizio Petitbon** Senior Advisor, BlackRock

- Advisor, entrepreneur and investor in healthcare space



Susan Coles **Vivet Therapeutics** General Counsel & Head of Finance

- 25+ years experience in international collaborations and corporate/ commercial activities



Oscar Izeboud Scenic Biotech CEO

- 20+ years of experience in biotech, including 14 years in investment banking

academic collaborations






Modulating Tumor Microenvironment Chemokines to Improve Cancer Therapy

The Tumor Microenvironment (TME) is a Key Hurdle to Solid Tumor Treatments



11



Sources: Haslam A. & Prasad V., JAMA Network Open. 2019;2(5):e192535. doi:10.1001/jamanetworkopen.2019.2535, Update suggests reduction to 36.1% eligibility and 10.9% response due to failed confirmatory trials in A. Haslam, J. Gill and V. Prasad JAMA Netw Open 2020 Vol. 3 Issue 3 Pages e200423

Cancers affected by immunology drugs = percentage of the total US cancer patient population eligible for an approved checkpoint immunotherapy Respond to immunology drugs = the overall response rate (complete plus partial) projected as a percentage of all US cancer patients TME Pharma's Drug Candidates Allow the Immune System to Penetrate Solid Tumor Defenses and Block Repair of Damaged Tumors



12




Figure adapted from Chen & Mellman 2013, Immunity 39:1.

(a) Liu 2014, Neuro-Oncology 16:21. Chernikova S et al., AACR-NCI-EORTC Int. Conf. on Molecular Targets and Cancer Therapeutics 2013. Deng L et al., Neoplasia (2017) 19, 1–7;


- (b) Giordano (2021) Society for Neuro-Oncology 2021 Annual Meeting Presentation CTNI-43 of phase I/II GLORIA trial (NCT04121455). Giordano (2022) American Society for Clinical Oncology 2022 Annual Meeting Poster #2050 of phase I/II GLORIA trial (NCT04121455).
- (c) Bartneck 2019, Cell Mol Gastroenterol Hepatol 7:371. Lazarus 2017, Poster PT165 Soc Surg Oncol 70th Annual Cancer Symposium.

Role of CXCL12 Chemokine Axis in Cancer **TME MOX-A12** Inhibition of CXCL12 Provides Strong Differentiation

Roles of CXCL12 / CXCR4 / CXCR7 Axis

- Establishment of tumor-promoting microenvironment excluding / sequestering effector T-cells and recruitment of immuno-suppressive cell populations
- Recruitment of endothelial progenitor cells (growth support, tumor vascularization)
- Stimulation of tumor growth
- Adhesion
- Chemotherapy resistance
- Spreading / metastasis

Blocking only CXCR4 is not sufficient for adequate control of the TME and may be counter-productive in certain cancer therapy contexts. Blocking CXCR7 has shown to be crucial in solid tumors such as brain and pancreatic cancer.



NOX-A12 BINDING OF THE CHEMOKINE CXCL12:

- 1) blocks receptor interaction with both CXCL12 receptors (CXCR4 and CXCR7) and down-stream signalling
- 2) neutralizes anchor domain detaching chemokine & destroying the location information of the chemokine concentration gradient

NOX-A12 – Dual Mechanism of Action




Blockage of Vasculogenesis:

Use in combination with anti-vascular agents such as radiotherapy or anti-VEGF-(R)


Overcome immune exclusion & prevent recruitment of immune-suppressive cells

Combos with CPIs, Bi-Specifics, Cell Therapies



TME Pharma at the Forefront of Chemokine Development for Cancer with Limited Direct Competition in Brain & Pancreatic Cancer





Includes assets in development worldwide from preclinical phase to registration.

Source: Citeline Clinical Intelligence Reports, TME Pharma analysis, February 2024

1. The IIT by L.D. Recht at Stanford studying whole brain radiation therapy (WBRT) with temozolomide and plerixafor in GBM has been resumed in H1 2023; 2. X4 Pharma outlicensed mavorixafor to Abbisko with the exclusive rights in Greater China to develop and commercialize mavorixafor in oncology indications – including pancreatic cancer. However, no clinical development in pancreatic cancer has been initiated by Abbisko since the deal announcement in 2019.




NOX-A12 + Radiotherapy \pm Bevacizumab in Chemotherapy Refractory Glioblastoma

Glioblastoma is a Devastating Orphan Brain Cancer where the TME Plays a Significant Role



LACK OF EFFECTIVE THERAPIES & LOW OVERALL SURVIVAL



NOX-A12 OFFERS CHEMO-FREE REGIMEN FOR HIGH UNMET NEED PATIENT SEGMENTS

CHEMO-RESISTANT

- >50% of GBM patients have unmethylated MGMT promoter leading to no significant benefit from chemotherapy and worse prognosis
- NOX-A12 trial omits chemotherapy improving overall safety profile and offers immune-friendly regimen

PARTIAL TUMOR RESECTION

 Patients with measurable tumor remaining after maximal safe surgical removal of cancer have worse prognosis vs. patients with complete tumor resection




NOX-A12 GLORIA study focuses on patients with tumor detectable after surgery that is chemotherapy resistant – the most difficult to treat patient population in GBM whose expected survival is approx. 10 months.

Sources: 1) In the US, UK, FR, ES, DE & IT, Global Data April 2022, 2) CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2016—2020. 3) Citeline Clinical Intelligence Phases 1 – IV trials in glioblastoma in North America or Europe analyzed 22 Feb 2024. Graph from Hegi ME et al. N Engl J Med 2005;352:997-1003

NOX-A12's MOA is Relevant to GBM: Attacking Key Survival Mechanisms Following Radiotherapy






Inhibition of the CXCL12/CXCR4/CXCR7 axis can block tumor vasculogenesis


NOX-A12 + Radiotherapy Increases Survival and Demonstrates Complete Regression of Brain Tumors



Autochthonous brain tumor model in rats

- Spontaneous tumor development in immuno-competent host
- Diversity of tumor cell types with therapeutic resistance comparable to human situation
- Refractory to standard therapies






NOX-A12 + radiotherapy resulted in 100% complete response (66% durable) in brain cancer rat model



1st line brain cancer (glioblastoma) with extremely poor prognosis due to:

- Incomplete surgical resection or biopsy only
- MGMT promoter unmethylated: chemotherapy ineffective

Expected median survival in this population receiving standard of care is approx. 10 months¹




1. Standard of care data from 20-patient matched reference cohort of newly diagnosed glioblastoma with MGMT unmethylated, incompletely resected or biopsy-only tumors; Giordano (2022) ASCO Annual Meeting Pres. #2050 2. CADD®-Solis VIP Ambulatory Infusion Pump by Smiths Medical 3. Bevacizumab (BEV).

20

NOX-A12 Combinations Improve Best Response Rates and Depth of Tumor Shrinkage vs. Standard of Care



(Matched reference cohort from center participating in trial: MGMT Unmethylated & incomplete surgical resection or biopsy only)



Radiotherapy + NOX-A12

Sources: Giordano (2022) ASCO Annual Meeting Presentation #2050; Giordano (2022) SNO Annual Meeting Poster Presentation #CTNI-67, Giordano (2023) ASCO Annual Meeting Poster Presentation #405 & TME Pharma Press Release from 19 November 2022, 26 May 2023, 13 July 2023, 2 February 2024


21

Radiotherapy + NOX-A12

+ anti-VEGF

NOX-A12 + RT + Bevacizumab: Final Survival Data median Overall Survival of 19.9 months






- Median overall survival (mOS): 19.9 months
- 2 out of 6 patients remain alive
- 50% overall survival at 21 months
- 5 out of 6 patients achieved durable mRANO responses >6 months

10-Fold Improvement in 21-month Survival for NOX-A12 + RT + anti-VEGF vs. Standard of Care





Since neither bevacizumab (anti-VEGF) alone, nor bevacizumab plus radiotherapy have previously been shown to extend survival², the strong increase in survival can be attributed to the complementary mechanism of action of NOX-A12 with bevacizumab and radiotherapy

1. Standard of care data from 20-patient matched reference cohort of newly diagnosed glioblastoma with MGMT unmethylated, incompletely resected or biopsy-only tumors; Giordano (2022) ASCO Annual Meeting Pres. #2050. NOX-A12 survival data from *TME Pharma* Press Release 2 February 2024; 2. Chinot (2014) NEJM, Gilbert (2014) NEJM, Herrlinger (2016) J Clin Oncology

Relevant Benchmark Studies in Chemotherapy Resistant Glioblastoma from US and EU




Experimental Agent (Company)	Surgical removal of detectable tumor (T=total; P=partial; B=biopsy only)	Patient number	Response criteria	Overall Response Rate (ORR)	Median Overall Survival (mOS) in months	Status	Reference
NOX-A12 + Radiotherapy + bevacizumab (TME Pharma)	0% T; 100% P	6	RANO	83%	19.9	Ph 1/2 ongoing, Orphan Drug Designation & Fast Track Designation granted	TME Pharma Internal Data
Tumor Treating Fields (TTF) + Radiotherapy + Temozolomide (Novocure)	53% T; 34% P; 13% B	209	Macdonald	n.a.	16.9	Approved	Stupp R (2017), JAMA
Val-083 after Radiotherapy + Temozolomide chemotherapy) (Kintara)	information not provided	36	RANO	n.a.	16.5	Failed pre-defined criteria for GBM AGILE trial Ph 3	O'Brien (2021), Society for Neuro-Oncology Annual Meeting
Paxalisib + Radiotherapy (Kazia)	77% T; 17% P; 10% B	30	RANO	3%	15.7	Failed pre-defined criteria for GBM AGILE trial Ph 3	Wen P (2022); J Clin Oncol.
Enzastaurin + Radiotherapy (Denovo)	43.9% T; 40.4% P; 15.8 B	57	Macdonald	7%	15	Orphan Drug Designation & Fast Track Designation granted; Ph 3 ongoing	Wick W (2013), Neuro Oncol.
Temozolomide chemotherapy + Radiotherapy + bevacizumab (Roche)	63% T; 34% P; 3% B #	215	Macdonald	n.a.	14.3	Failed in Ph 3	Gilbert MR (2014), NEJM
Nivolumab anti-PD-1 immunotherapy + Radiotherapy (BMS)	54% T; 46% P	280	RANO	7.8%	13.4	Failed in Ph 3	Omuro A (2022); Neuro Oncol.
Temozolomide chemotherapy + Radiotherapy	information not provided	60	n.a.	n.a.	12.7	Approved (current standard of care)	Hegi ME (2005) NEJM

Higher Survival at 21 Months with NOX-A12 + BEV Than Seen in Benchmark BEV Studies Enrolling Patients with Better Prognosis




OS at 21 months:

Benchmark Phase 2 study with only MGMT <u>un</u>methylated patients but incl. gross total resection



OS at 21 months:

Benchmark Phase 3 studies with mixed populations in terms of MGMT and resection



Superior survival signal of NOX-A12 + BEV vs. TMZ + BEV even when tested in patients with worse prognosis

FDA-Approved Phase 2 Study Design in GBM: 5-arm Randomized Controlled Study, 20 Patients / Arm




- Newly diagnosed glioblastoma patients with extremely poor prognosis:
 - Incomplete surgical resection
 - MGMT promoter unmethylated: chemotherapy ineffective
- Randomized-controlled
 enrollment
- Treatment duration 1 to 2 years

Expected survival in this population receiving standard of care¹:

• mOS of approx. 10 months


Orphan Drug and Fast Track Designations awarded by FDA



1. Standard of care data from 20-patient matched reference cohort of newly diagnosed glioblastoma with MGMT unmethylated, incompletely resected or biopsy-only tumors; Giordano (2022) ASCO Annual Meeting Pres. #2050

The EG12 Score: A Potential Predictive Biomarker for Clinical Outcome

- A predictive biomarker is a measurable biological characteristic that provides information about the likelihood of an individual patient to respond to a specific treatment
- Analysis of tumor tissue revealed that the EG12 score strongly and significantly correlated with PFS in GLORIA patients receiving NOX-A12 + RT (p=0.005) but not in patients treated with standard of care (p=0.724)
- The EG12 score predicts PFS for NOX-A12-treated patients with statistical significance (p=0.031)



There is also a strong trend for the EG12 score to predict OS for NOX-A12 treated patients (p=0.075)

The EG12 score might be a **predictive biomarker for OS** in patients treated with NOX-A12 + RT


Standard of Care



NOX-A12 + RT + Bevacizumab: Near-Complete Response in Exemplary Patient



NOX-A12 + BEV



Radiographic treatment course of an exemplary patient A-001 with target lesion (TL), non target lesions (NTLs) and MRI volumetric, diffusion (ADC) and perfusion (rCBV, FTBhigh) parameters (treatment ongoing)

pPR – preliminary partial response cPR – confirmed partial response


Changes from baseline ADC: increase in change represents improvement rCBV, Volume, FTBhigh: decrease in change represents improvement

\rightarrow >99% reduction

cut off date: 01-Nov-2022


Sources: Giordano (2022) SNO Annual Meeting Poster Presentation #CTNI-67 & *TME Pharma* Press Release from 19 November 2022

NOX-A12 Neutralizes the CXCL12 Chemokine on Blood Vessel TME 🕥 Walls in GBM Patient




NOX-A12 + RT Reduce Tumor Cell Proliferation in GBM Patient





Source: Giordano (2021) Society for Neuro-Oncology 2021 Annual Meeting Presentation CTNI-43 – of phase I/II GLORIA trial (NCT04121455)


NOX-A12 + RT Lead to Extensive Penetration of Immune System (Cytotoxic T Cells) in the Tumor of GBM Patient




Images show areas of pathologist-confirmed tumor tissue

Source: Giordano (2021) Society for Neuro-Oncology 2021 Annual Meeting Presentation CTNI-43 – of phase I/II GLORIA trial (NCT04121455)

NOX-A12 + RT = Anti-Cancer Cells + Pro-Cancer Cells



Macrophages



- Substantial increase in cytotoxic T cells in two patients under treatment with NOX-A12
- Increased proportion of activated and proliferating cytotoxic T cells as well as T cell cluster formation in two patients under treatment with NOX-A12

Increased anti-cancer macrophages in two patients under treatment with NOX-A12

- Increase in anti-cancer macrophages (M1-like)
- No consistent change in pro-cancer macrophages (M2-like)

TME

Good Safety, Tolerability and Promising Efficacy Data in NOX-A12 and NOX-A12 + Bevacizumab Arms




- **Good safety and tolerability** profile of all combinations
- Tissue analysis confirms mode(s) of action^{2,3}
- **Potential biomarker identified** which is **predictive for PFS** in patients treated with NOX-A12 + RT⁷
- **Promising response rates** for the combination of NOX-A12 + RT and for NOX-A12 + RT + BEV^{3,5}
- Clinical outcome beyond expectation for the study population⁸
- NOX-A12 + RT + BEV:
 - 19.9 months mOS vs. 10.5 months for Standard of Care
 - 10-fold improvement of 21-month survival vs. Standard of Care (50% vs. 5%)
- Regulatory status:
 - **Open IND** for upcoming Phase 2 in newly diagnosed, chemotherapy-resistant glioblastoma with residual tumor post-surgery, **Fast Track Designation** awarded by the FDA
 - Orphan Drug Designation in the EU and US
- Future development potential
 - The MoA of NOX-A12 also supports development of NOX-A12 in MGMT methylated patients, in recurrent glioblastoma as well as in brain metastases from other cancer types (e.g. breast and lung)

Sources: 1) Radiographic partial response; 2) Giordano (2021) Society for Neuro-Oncology 2021 Annual Meeting Presentation CTNI-43; 3) Giordano (2022) ASCO Annual Meeting Presentation #2050; 4) Wick, W. (2013) J. Clin. Oncol. Vol 31, 15 suppl 2002; 5) Giordano (2022) SNO Annual Meeting Poster Presentation #CTNI-67 & TME Pharma Press Release from 19 Nov 2022; 6) Disease control rate which also includes patients that had an increase of tumor size up to 25%; 7) Giordano (2023) ASCO Annual Meeting Presentation #405; 8) TME Pharma Press Releases 10 October 2023 and 20 October 2023, 2 February 2024, 2 April 2024

NOX-A12 + Immunotherapy in Pancreatic Cancer

Pancreatic Cancer – Extremely Low Overall Survival and Limited Treatment Options





2

FOLFIRINOX

Gem/Abraxane

Onivvde

5FU/LV

1. Second-line In the US, UK, FR, ES, DE & IT, 107k first-line. Global Data April 2022

24

36

Months

48

60

12

10-


Sources: Sun, H. (2015) Scientific Reports 4, 6747.doi:10.1038/srep06747; S. Pusceddu, M, et al. (2019) Cancers Vol. 11 Issue 4; Seo YD, et al., (2019) Clin Cancer Res; 25(13); Global Data, ClinicalTrials.gov & TME Pharma analysis, April 2022

NOX-A12 + Immunotherapy: Mode of Action



CXCL12:

- excludes effector immune cells from entering the tumor
- attracts bone-marrow derived immuno-suppressive / pro-cancer cells to region of tumor




NOX-A12 + Immunotherapy: Mode of Action



NOX-A12:

- reduces CXCL12 "wall" around solid tumors, which
- allows Killer T Cells to enter, eliminates attraction of immuno-suppressive / pro-cancer cells¹




NOX-A12 + Immunotherapy: Mode of Action




NOX-A12:

- reduces CXCL12 "wall" around solid tumors, which
- allows Killer T Cells to enter, eliminates attraction of immuno-suppressive / pro-cancer cells¹



Phase 1/2 Trial Completed in 9 Pancreatic Cancer and 11 Metastatic Colorectal Cancer Patients







In PDAC / CRC Patients NOX-A12 Monotherapy Induces Integrated Immune Response and T Cell Clustering


Cytokine profile

Unsupervised clustering of patients based on relative changes in the molecular immune landscape at the end of NOX-A12 monotherapy. Concentrations of the most affected cytokines before and at the end of the monotherapy in patients clustered in tissue responders (TR) and tissue nonresponders (TNR).






distance to tumor (distance bands)



T-cell clustering in PaC/CRC patients on NOX-A12 monotherapy similar to that seen in glioblastoma patients while on NOX-A12 therapy post-RT with infiltration of proliferating GNZB+/CD8+ cells


Impressive Survival in Heavily Pre-Treated Patients





Overall Survival Longer Than Expected for this Heavily Pre-Treated Population





Of the 5 stable disease patients (25% of the study population) **3 survived for more than a year**

Status and Next Steps in Development of NOX-A12 in Pancreatic Cancer



- Phase 2 designed to position NOX-A12 + immunotherapy as Standard of Care in 2nd line pancreatic cancer
- Design tests 2 arms, each with NOX-A12 + pembrolizumab combined with either gemcitabine/Abraxane[®] or Onivyde[®]/5FU/LV
- Protocol approved by regulators in France and Spain and by US FDA



NOX-A12: Two Orphan Indications with ~\$8.5bn Total Addressable Market



	NOX-A12 Brain Cancer Fast Track & Orphan Drug Status Granted	NOX-A12 Pancreas Cancer
Target population US & EU – New cases per year	29,000	69,000 (2 nd line) 107,000 (1 st line)
Expected duration of treatment based on median OS	>12 months	>12 months
\$ Total Addressable Market ¹	\$2.5 bn (1 st line)	\$6bn (2nd line) \$9.3bn (1 st line)
Next inflection points	Financing & initiation of randomized Phase 2	Financing & initiation of randomized Phase 2

4



Thank you.

Contact us: tme@tmepharma.com